AdaptHealths Earnings Miss Ignite Sell-Off Despite Revenue Beat

AdaptHealth (AHCO) reported fiscal 2025 Q4 earnings on Feb 24, 2026, with revenue beating expectations but a sharp decline in profitability. The company outlined 2026 guidance aligning with its capitated contract expansion, though investors reacted negatively to the earnings miss.

Revenue

AdaptHealth’s total revenue declined 1.2% year-over-year to $846.29 million in Q4 2025, slightly below the $856.64 million reported in Q4 2024. Within the segment breakdown, Sleep Health led with $372.3 million in net revenue, reflecting a 4.4% year-over-year increase. Respiratory Health contributed $178.2 million, up 7.8% year-over-year, driven by growth in oxygen and ventilator new starts. Wellness and other segments, while not quantified, were highlighted for record patient census metrics.

Earnings/Net Income

The company swung to a loss of $0.74 per share in Q4 2025, a 316.2% deterioration from a $0.34 profit in Q4 2024. Net income plummeted to a $101.54 million loss, compared to $51.40 million in the prior year. This stark reversal underscores significant profitability challenges despite revenue resilience.

Price Action

AdaptHealth’s stock price has continued its downward trajectory, falling 11.89% in a single trading day, 14.03% for the week, and 15.67% month-to-date. The post-earnings sell-off reflects investor skepticism about the company’s ability to sustain margins amid its strategic transition.

Post-Earnings Price Action Review

The strategy of buying AdaptHealth shares after its Q4 revenue decline and holding for 30 days has historically underperformed. Over three years, the approach yielded a -65.23% return versus a 61.87% benchmark, with a -127.10% excess return and a -23.62% CAGR. The strategy faced a maximum drawdown of 78.76% and a Sharpe ratio of -0.65, underscoring its volatility and risk profile.

CEO Commentary

CEO Suzanne Foster emphasized progress in operational standardization, debt reduction, and the successful rollout of the Mid-Atlantic capitated contract. She highlighted Q4 revenue exceeding guidance, driven by 1.7% organic growth and record patient census in key segments. Foster expressed confidence in 2026, citing regulatory clarity and $25 million in Q4 debt reduction.

Guidance

CFO Jason Clemens outlined 2026 guidance: revenue of $3.44–$3.51 billion (6–8% growth), adjusted EBITDA of $680–$730 million (20.3% margin), and free cash flow of $175–$225 million. Q1 2026 revenue is expected to grow 2–3% year-over-year, with capitated revenue driving incremental gains. Free cash flow is projected to turn positive in the second half of 2026.

Additional News

AdaptHealth expanded its footprint through the acquisition of a Hawaii-based HME provider and completed a strategic divestiture in Q4 2025. These moves align with CEO Suzanne Foster’s focus on operational efficiency and balance sheet strength. No C-level changes were reported, and the company remains silent on dividend or buyback initiatives.